Investor Relations

Corporate Profile

Fractyl Health is a clinical-stage metabolic therapeutics company focused on pioneering new approaches to treat obesity and T2D. Our Revita® and Rejuva® platform candidates are designed to target root causes of metabolic diseases and break the pattern of metabolic disease treatment from chronic management to potentially prevent and reverse metabolic disease. Fractyl Health is based in Burlington, Massachusetts.

Corporate Presentation 
 

REMAIN-1 Weight Maintenance Program Update

Minimum 15 minutes delayed. Source: LSEG

News Releases

View All

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

May 12, 2026

Read More

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

May 11, 2026

Read More

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

May 5, 2026

Read More

Events

View All

BofA Securities 2026 Health Care Conference

May 14, 2026 | 12:20 PM EDT

Read More

Fractyl Health 1Q 2026 Financial Results and Business Update Conference Call

May 12, 2026 | 4:30 PM EDT

Read More

SEC Filings

View All

SCHEDULE 13G/A - Description

| Form Type: SCHEDULE 13G/A

SCHEDULE 13G/A

SCHEDULE 13G/A - Description

| Form Type: SCHEDULE 13G/A

SCHEDULE 13G/A

Investor Relations Contacts

Brian Luque, Head of Investor Relations and Corporate Development

Email: ir@fractyl.com 
Phone: 951.206.1200